专利申请涉及的生物材料保藏

2015-04-22 MedSci MedSci原创

生物技术领域,如果专利申请涉及的必须使用的生物材料是公众不能得到的,同时因文字记载有时很难描述生命实体的具体特征,为使所属技术领域的技术人员能够实施该发明,专利法规定了申请人应该保藏所使用的生物材料。 简单说,凡是在发明的技术方案中必须使用,而公众在申请日前又不能得到的生物材料,都需要保藏。 例如:大多数由自然界筛选的特定微生物和通过物理化学方法进行人工诱变所生产的新微生物应进行保藏。

生物技术领域,如果专利申请涉及的必须使用的生物材料是公众不能得到的,同时因文字记载有时很难描述生命实体的具体特征,为使所属技术领域的技术人员能够实施该发明,专利法规定了申请人应该保藏所使用的生物材料。

简单说,凡是在发明的技术方案中必须使用,而公众在申请日前又不能得到的生物材料,都需要保藏。
例如:大多数由自然界筛选的特定微生物和通过物理化学方法进行人工诱变所生产的新微生物应进行保藏。


根据《布达佩斯条约》的规定,为了方便各国申请人向其他国家提交专利申请,各缔约国允许或者要求保藏用于专利程序的微生物的,应承认为此种目的而在任一国际保藏单位所作的微生物保藏,而不需要在各缔约国保藏单位分别提交保藏。这种承认包括承认该国际保藏单位说明的保藏事实和保藏日期,以及承认提供的样品是所保藏的微生物样品。

申请人需注意的情况:


1)申请人需在申请日之前,最迟申请日,将生物材料按规定进行保藏。
2)申请人需在申请日起四个月内提交保藏单位出具的保藏证明和存活证明。
3)申请人应在请求书和说明书中均写明生物材料的分类命名、拉丁文学名、保藏该生物材料样品的单位名称、地址、保藏日期和保藏编号。
4)将该生物材料的保藏日期、保藏单位全称及简称和保藏编号作为说明书的一个部分集中写在相当于附图说明的位置。

例如:



5)用于专利程序的生物材料的保藏期限至少30年,自保藏单位收到生物材料之日起计算。
6)在发明专利的初步审查程序中,一般会对生物材料的保藏情况进行初步审查。
7)对于生物技术领域,如果没有对必要生物材料进行保藏,将会导致说明书的公开不充分,专利申请将被驳回。


国家知识产权局认可的保藏单位:

一、 中国普通微生物菌种保藏管理中心(CGMCC)

(从1985年2月28日开始接受保藏申请)

1、保藏范围

1) 受理保藏的微生物种类:除中国政府规定的人和动物的一类危险病原菌以外的细菌,酵母菌,丝状真菌,支原体,动物病毒※,植物病毒※,噬菌体和质粒, 单细胞藻类,动物细胞系,植物细胞系,植物种子。

2)※ 一些动物病毒的存活检测需要动物宿主,这是中国普通微生物保藏中心不能提供的。这种情况下,寄存要求将被拒绝。不能用机械方式增殖的植物病毒也将被拒绝接受。 

3)不受理下述各类生物材料的保藏:a.原生动物;b.中国法律禁止入境的微生物;c.潜在危险性太大的微生物。 

2、联系方式

   网址:http://www.cgmcc.net 
   保藏单位名称:中国普通微生物菌种保藏管理中心
地址:北京市朝阳区北辰西路1号院3号  邮编 100101
开户银行:中国工商银行北京市海淀西区支行
开户单位:中国科学院微生物研究所
帐号:020000450908911742
用途:专利生物材料保藏费

3、收费标准

1)三十年保藏费:5000元。
2)发布存活性检测报告
细菌(无质粒),丝状真菌,酵母菌,单细胞藻类,支原体:500元。
动物和植物病毒,含有质粒的细菌:费用决定于各别案例。
3)提供样品:500元。
4)信息通讯费:200元。

二、中国典型培养物保藏中心(CCTCC)

(从1985年3月8日开始接受保藏申请)

1、保藏范围

1)专利的微生物菌种的保藏

细菌、放线菌、酵母菌、丝状真菌、高等真菌、单细胞藻类、地衣;动物细胞系、植物组织培养、原生动物、病毒(包括动植物病毒、噬菌体);质粒、基因片段、基因文库、植物种子、其它生物材料以及混合微生物。(最高物理防范等级不超过P2级)

除人和动物的一、二类病源以外的微生物(生物材料),根据一般原则,CCTCC仅受理现行的技术条件下长期保存时,其性状不发生明显变异的培养物;对一些较为特殊的生物材料,如必须保持其生命活动状态,可依据具体情况加以受理,但应事先协商。 

2)准备申请专利的微生物菌种的保藏

本保藏中心接收国内外准备申请专利的微生物(生物材料)的寄存,双方可签订保密协议,
在申请专利后转为专利程序的微生物保藏,但保藏日期为第一次提交保藏的原始保藏日。这样可避免申请专利时遗忘菌种保藏事宜。

2、联系方式

    网址:http://www.cctcc.org/index.php
    保藏单位名称:中国典型培养物保藏中心
    地址:湖北省武汉市武昌区八一路299号武汉大学校内(武汉大学第一附小对面) 邮编 430072
    开户银行:中国银行东湖开发区支行
    开户单位:武汉大学
    帐号:576857528447
    用途:专利生物材料保藏费

3、收费标准

专利培养物保藏

1)三十年保藏费及发放存活检测报告:5000元
如果是非条约下保存的用户,保藏费用可申请减免,最低收费不低于三十年保藏费的40%(2000元)。
2)应要求再次补充发布存活性检测报告
细菌(无质粒)、丝状真菌、酵母菌、单细胞藻类、支原体、细胞系、原生动物、种子:500元。
动物和植物病毒、植物细胞培养、含有质粒的细菌:费用决定于各别案例。
3)提供样品:500元。
4)信息通讯费:200元。
5)出入境许可证申请:按实际情况收取费用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    哦…

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    哦…

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    关注总归会有好处的!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    关注总归会有好处的!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    哦…

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    哦…

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]
    2016-01-12 medsic

    哦…

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1704909, encodeId=966d1e0490984, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Thu Jan 28 11:22:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56231, encodeId=d3e0562311e, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56232, encodeId=0451562320f, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56233, encodeId=953d56233fb, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56234, encodeId=503856234d5, content=关注总归会有好处的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56235, encodeId=15ec562353f, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:10:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56228, encodeId=bed95622831, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56229, encodeId=6a4756229d9, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56230, encodeId=bc0156230df, content=哦…, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:09:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076908, encodeId=907920e6908d0, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sat Sep 19 09:22:00 CST 2015, time=2015-09-19, status=1, ipAttribution=)]

相关资讯

国外企业在华中药专利申请态势分析

2014年底,德国拜耳36亿元完成对滇虹药业整体收购在业界引起强烈反响。而瑞士诺华制药早在2009年就高调宣布,将针对中国市场研发中草药,并欲有条件收购中国本土药企。可见,国外企业进军中国中药市场,利用专利在目标市场进行布局正是国外企业开拓海外市场的重要手段之一。笔者试图通过分析国外申请人在中药领域的专利申请特点和技术发展趋势,为国内中药产业和企业提供参考。 需要说明的是,本文所指的中药

专利申请须知:外观设计专利申请材料

外观设计专利申请需准备的资料:应提供:外观设计产品的六面视图、立体参考图及外观设计简要说明。六面视图:主视图,后视图,左视图,右视图,俯视图,仰视图。立体参考图:能同时展示三个面的视图。简要说明:1.外观设计产品的名称;2.外观设计产品的用途;3.外观设计产品的设计要点(形状、图案、色彩);4.最能表明设计要点的图片;5.省略视图说明,透明部分的说明,基本设计的指定。

专利申请的十一大误区

随着近几年国家对知识产权的重视,国内的企业对专利在提升核心竞争力方面的作用有了进一步的认识,纷纷加强了专利工作,专利申请量大幅度增加,但是在专利代理过程中,笔者发现不少企业在专利申请过程中,仍存在误区,需要早日改进。误区一:自主研发的成果不申请专利就有知识产权。一些技术人员认为只要是自主创新,就有了自主知识产权。其实不然,专利是一种垄断权,自主研发的技术成果如果不申请专利,就得不到法律确认和保

带你熟悉--专利申请号

专利申请号 是指国家知识产权局受理一件专利申请时给予该专利申请的一个标识号码。 特点 一个专利申请号只可能用于一件专利申请,即使在一件专利申请或由此取得的专利权灭失之后,任何其他专利申请也不再可能使用该专利申请号。 专利申请号的组成 包括申请年号、申请种类号、申请流水号三个部分。 校验位:是1位阿拉伯数字(0至9)或大写英文字母X。 校验位位于专利申请号之后,在专利申请号与校验位之间

各国及各行业的专利申请状况

各国及各行业的专利申请状况 (摘自国家知识产权局) 随着知识经济和经济全球化深入发展,知识产权日益成为发展的重要资源和竞争力的核心要素,截至2013年,我国发明专利申请量连续3年居世界首位,知识产权对经济转型发展的推动作用不断凸显,对创新驱动发展战略的支撑作用不断增强。 如下数据可显现出近年来国家及各行业对专利的重视程度: 2014年国内发明专利受理状况:

专利申请须知:技术交底书

什么是技术交底书?技术交底书是揭露一项专利申请的完整技术方案的文档,它包括特定的组成部分,由申请人起草,是整个专利流程的发起端。技术交底书的重要性其撰写的质量高低直接影响专利代理人对该专利申请的技术方案的理解与把握,是左右专利代理人起草符合专利法规定的申请文件的关键因素。如何撰写技术交底书发明/实用新型专利申请技术资料交底要求:1.名称:简明表述要保护的主题名称,名称应体现是产品或方法(一般25个